Investor Spotlight: Illumina Ventures

Feb 8 2018

Let's get more solutions to patients. The Johnson & Johnson Innovation, JLABS (JLABS) Meet with… Series helps life sciences entrepreneurs, as well as the academic community, connect with potential partners including corporate venture, VC's, Angels and other investment entities.

On February 8th 2018, investment team members at Illumina Ventures, Wouter Meuleman and Noel Jee, will give an overview presentation about the venture capital firm’s key areas of interest. Following the presentation, you’ll have the opportunity to introduce yourself to Wouter and Noel during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Illumina Ventures provides an intimate forum to discuss your company.

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due January 18th, 2018. Apply Here.

Program Overview:
Illumina Ventures is a life sciences VC fund with an emphasis on genomics and a partnership with Illumina, Inc. The $200M+ fund invests primarily in Series A tools, diagnostics, and therapeutics companies with a focus on early-stage, disruptive technologies and platforms. While the fund focuses on genomics, they also invest more broadly in the life sciences space.

Areas of Interest include:

  • Genomics Research and Tools
  • Therapeutics companies and discovery platforms (e.g., oncology, infectious disease)
  • Reproductive Health
  • Agrigenomics
  • Applied Genomics
  • Complex Diseases
  • Microbial Genomics and Microbiome
  • Informatics and Genomics Analysis

Following the presentation, don't miss this opportunity to introduce yourself to Wouter & Noel during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Illumina Ventures will provide an intimate forum to discuss your company.

10:30 AM | Registration and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking and Lunch
12:30 PM - 5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on January 18th, 2017.

$15 | General Public
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on February 7th (or sold out).

JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, Ontario

Illumina Ventures Participating Representatives:
Wouter Meuleman PhD | Director of Investments
Wouter is Director of Investments at San Francisco-based Illumina Ventures. Prior to Illumina Ventures, Wouter worked at Illumina, Inc. in various roles throughout the organization including R&D, Product Development, and Corporate Development. A physical chemist by training, he began his career in life sciences as first hire for Oxford University spin-out Oxamer, a company founded in 2003 by Prof. Sir Edwin Southern, where he led the development a benchtop DNA microarray fabrication platform. Following the company’s incorporation into Oxford Gene Technology in 2005, he continued working alongside Prof. Southern leading R&D programs in areas such as single cell gene expression analysis and novel applications for DNA microarrays. He obtained his undergraduate and Master’s degree in Chemistry from the University of Ghent, Belgium; a PhD in Chemical Engineering from the University of Newcastle, U.K; and an MBA from the University of Cambridge, U.K.
Connect with Wouter:   Connect on LinkedIn

Noel Jee PhD | Investment Associate
Noel is an Investment Associate at Illumina Ventures. Prior to joining the fund, Noel worked at L.E.K. Consulting as a management consultant specializing in the life sciences. He has consulted on strategy engagements for companies in the pharmaceuticals, biotech, and diagnostics industries. Before joining L.E.K. Consulting, Noel helped to co-found and bootstrap the San Francisco-based medical device and digital health startup Knox Medical Diagnostics, where he led the initial business development. He obtained a dual B.S. degree from the University of Maryland College Park, and his PhD in Chemistry and Chemical Biology from the University of California San Francisco.
Connect with Noel:   Connect on LinkedIn